
Promising results from a phase 1 clinical trial evaluating HFB30132A, an anti-SARS-CoV-2 monoclonal antibody, have been reported. The study found that HFB30132A was safe and well-tolerated in healthy Chinese subjects, with no immunogenic response detected. The antibody exhibited neutralizing activity against various virus variants and a prolonged half-life. These findings support the potential development of HFB30132A in combating COVID-19
Like
Save
Share